Najeeb Al Hallak Mohammed, McCurdy Matt, Zouain Nicolas, Hayes Justin
University of North Dakota School of Medicine and Health Sciences, Fargo, N. Dak., USA.
Case Rep Oncol. 2009 Aug 28;2(2):157-161. doi: 10.1159/000235809.
(153)Sm-EDTMP is a radiopharmaceutical composed of EDTMP (ethylenediamine-tetramethylenephosphonate) and Samarium-153 [1]. (153)Sm-EDTMP has an affinity for skeletal tissue and concentrates in areas with increased bone turnover; thus, it is successfully used in relieving pain related to diffuse bone metastases [1]. The manufacturing process of (153)Sm-EDTMP leads to contamination with (154)Eu (Europium-154) [2]. A previous study only alluded to the retention of (154)Eu in the bones after receiving treatment with (153)Sm-EDTMP [2]. Activation of the alarm at security checkpoints after (153)Sm-EDTMP therapy has not been previously reported. Two out of 15 patients who received (153)Sm-EDTMP at Roger Maris Cancer Center (Fargo, N. Dak., USA) activated the radiation activity sensors while passing through checkpoints; one at a US airport and the other while crossing the American-Canadian border. We assume that the (154)Eu which remained in the patients' bones activated the sensors. METHODS: In order to investigate this hypothesis, we obtained the consent from 3 of our 15 patients who received (153)Sm-EDTMP within the previous 4 months to 2 years, including the patient who had activated the radiation alarm at the airport. The patients were scanned with a handheld detector and a gamma camera for energies from 511 keV to 1.3 MeV. RESULTS: All three patients exhibited identical spectral images, and further analysis showed that the observed spectra are the result of (154)Eu emissions. CONCLUSION: Depending on the detection thresholds and windows used by local and federal authorities, the remaining activity of (154)Eu retained in patients who received (153)Sm-EDTMP could be sufficient enough to increase the count rates above background levels and activate the sensors. At Roger Maris Cancer Center, patients are now informed of the potential consequences of (153)Sm-EDTMP therapy prior to initiating treatment. In addition, patients treated with (153)Sm-EDTMP at Roger Maris Cancer Center receive laminated cards stating the date and the dose of treatment, as well as a statement that the holder may activate the alarm at the security checkpoints.
(153)钐-乙二胺四甲基膦酸盐(Sm-EDTMP)是一种由乙二胺四甲基膦酸盐(EDTMP)和钐-153组成的放射性药物[1]。(153)Sm-EDTMP对骨骼组织具有亲和力,并在骨转换增加的区域聚集;因此,它已成功用于缓解与弥漫性骨转移相关的疼痛[1]。(153)Sm-EDTMP的制造过程会导致被(154)铕(铕-154)污染[2]。先前的一项研究仅提及在接受(153)Sm-EDTMP治疗后(154)铕在骨骼中的滞留情况[2]。此前尚未有关于(153)Sm-EDTMP治疗后安检点警报被触发的报道。在美国北达科他州法戈市的罗杰·马里斯癌症中心,15名接受(153)Sm-EDTMP治疗的患者中有两名在通过安检点时触发了辐射活动传感器;一次是在美国机场,另一次是在跨越美加边境时。我们推测留在患者骨骼中的(154)铕激活了传感器。方法:为了研究这一假设,我们征得15名在过去4个月至2年期间接受过(153)Sm-EDTMP治疗的患者中的3名同意,其中包括在机场触发辐射警报的患者。使用手持式探测器和伽马相机对患者进行扫描,扫描能量范围为511千电子伏特至1.3兆电子伏特。结果:所有三名患者呈现出相同的光谱图像,进一步分析表明观察到的光谱是(154)铕发射的结果。结论:根据地方和联邦当局使用的检测阈值和窗口,接受(153)Sm-EDTMP治疗的患者体内残留的(154)铕活性可能足以使计数率高于背景水平并触发传感器。在罗杰·马里斯癌症中心,现在会在开始治疗前告知患者(153)Sm-EDTMP治疗的潜在后果。此外,在罗杰·马里斯癌症中心接受(153)Sm-EDTMP治疗的患者会收到一张层压卡片,上面注明治疗日期和剂量,以及持卡人可能会在安检点触发警报的说明。